Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1996 1
2011 1
2020 4
2021 4
2022 14
2023 5

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Results by year

Filters applied: . Clear all
Page 1
Effect of herbal extracts and Saroglitazar on high-fat diet-induced obesity, insulin resistance, dyslipidemia, and hepatic lipidome in C57BL/6J mice.
Kumari D, Gautam J, Sharma V, Gupta SK, Sarkar S, Jana P, Singhal V, Babele P, Kamboj P, Bajpai S, Tandon R, Kumar Y, Dikshit M. Kumari D, et al. Heliyon. 2023 Nov 4;9(11):e22051. doi: 10.1016/j.heliyon.2023.e22051. eCollection 2023 Nov. Heliyon. 2023. PMID: 38027691 Free PMC article.
We evaluated the effects of select herbal extracts (Tinospora cordifolia [TC], Tinospora cordifolia with Piper longum [TC + PL], Withania somnifera [WS], Glycyrrhiza glabra [GG], AYUSH-64 [AY-64], and Saroglitazar [S]) on various parameters in a diet-induced …
We evaluated the effects of select herbal extracts (Tinospora cordifolia [TC], Tinospora cordifolia with Piper longum [TC + PL], Withania so …
Evaluation of Ayush-64 (a Polyherbal Formulation) and Its Ingredients in the Syrian Hamster Model for SARS-CoV-2 Infection Reveals the Preventative Potential of Alstonia scholaris.
Rizvi ZA, Madan U, Tripathy MR, Goswami S, Mani S, Awasthi A, Dikshit M. Rizvi ZA, et al. Pharmaceuticals (Basel). 2023 Sep 21;16(9):1333. doi: 10.3390/ph16091333. Pharmaceuticals (Basel). 2023. PMID: 37765142 Free PMC article.
In the current study, we evaluated the efficacy of Ayush-64 (A64), a polyherbal formulation containing Alstonia scholaris (L.) ...
In the current study, we evaluated the efficacy of Ayush-64 (A64), a polyherbal formulation containing Alstonia scholaris (L.) …
Co-administration of AYUSH 64 as an adjunct to standard of care in mild and moderate COVID-19: A randomized, controlled, multicentric clinical trial.
Chopra A, Tillu G, Chuadhary K, Reddy G, Srivastava A, Lakdawala M, Gode D, Reddy H, Tamboli S, Saluja M, Sarmukaddam S, Gundeti M, Raut AK, Rao BCS, Yadav B, Srikanth N, Patwardhan B. Chopra A, et al. PLoS One. 2023 Mar 16;18(3):e0282688. doi: 10.1371/journal.pone.0282688. eCollection 2023. PLoS One. 2023. PMID: 36928877 Free PMC article. Clinical Trial.
OBJECTIVE: Evaluate the efficacy of AYUSH 64, a standard polyherbal Ayurvedic drug in COVID-19. METHODS: During the first pandemic wave, 140 consenting and eligible hospitalized adult participants with mild-moderate symptomatic disease (specific standard RT-PCR assa …
OBJECTIVE: Evaluate the efficacy of AYUSH 64, a standard polyherbal Ayurvedic drug in COVID-19. METHODS: During the first pand …
AYUSH (Indian System of Medicines) Therapeutics for COVID-19: A Living Systematic Review and Meta-Analysis (First Update).
Thakar A, Panara K, Goyal M, Kumari R, Sungchol K. Thakar A, et al. J Integr Complement Med. 2023 Mar;29(3):139-155. doi: 10.1089/jicm.2022.0559. Epub 2022 Nov 2. J Integr Complement Med. 2023. PMID: 36322891 Review.
This study assessed the effectiveness of AYUSH therapeutic on COVID-19 through a living systematic review and meta-analysis approach. ...Results: Of 3609 studies retrieved, 17 were included in the systematic review, and 3 AYUSH therapeutics were meta-analyzed. Meta- …
This study assessed the effectiveness of AYUSH therapeutic on COVID-19 through a living systematic review and meta-analysis approach. …
In vitro effect of Withania somnifera, AYUSH-64, and remdesivir on the activity of CYP-450 enzymes: Implications for possible herb-drug interactions in the management of COVID-19.
Kasarla SS, Borse SP, Kumar Y, Sharma N, Dikshit M. Kasarla SS, et al. Front Pharmacol. 2022 Oct 12;13:973768. doi: 10.3389/fphar.2022.973768. eCollection 2022. Front Pharmacol. 2022. PMID: 36313313 Free PMC article.
Ayurvedic medicines Withania somnifera Dunal (ashwagandha) and AYUSH-64 have been used for the prevention and management of COVID-19 in India. ...Aqueous extracts of ashwagandha and AYUSH-64 were characterized using LC-MS/MS. A total of 11 and 24 phyto …
Ayurvedic medicines Withania somnifera Dunal (ashwagandha) and AYUSH-64 have been used for the prevention and management of CO …
A methodological analysis of CTRI registered clinical trials on ayurveda interventions for COVID-19 management.
Chaudhari SS, Somvanshi PR. Chaudhari SS, et al. J Ayurveda Integr Med. 2023 Jan-Feb;14(1):100631. doi: 10.1016/j.jaim.2022.100631. Epub 2022 Aug 11. J Ayurveda Integr Med. 2023. PMID: 35971456 Free PMC article.
Most common intervention used were guduchi, ashwagandha, yashtimadhu, AYUSH-64, curcumin and chyavanprash. CONCLUSION: Although there was a surge of clinical trials on CTRI regarding ayurveda for COVID -19, the methodological quality is not up to the mark with large …
Most common intervention used were guduchi, ashwagandha, yashtimadhu, AYUSH-64, curcumin and chyavanprash. CONCLUSION: Althoug …
Disease Characteristics, Care-Seeking Behavior, and Outcomes Associated With the Use of AYUSH-64 in COVID-19 Patients in Home Isolation in India: A Community-Based Cross-Sectional Analysis.
Srikanth N, Kumar A, Chandrasekhararao B, Singhal R, Yadav B, Khanduri S, Jameela S, Rai AK, Tripathi A, Rana R, Ahmad A, Sharma BS, Jaiswal A, Kotecha R; State Level Collaborators. Srikanth N, et al. Front Public Health. 2022 Jul 6;10:904279. doi: 10.3389/fpubh.2022.904279. eCollection 2022. Front Public Health. 2022. PMID: 35900336 Free PMC article.
BACKGROUND: During the second wave of the COVID-19 pandemic in India, the Ministry of Ayush conducted a community study to provide therapeutic care to patients with asymptomatic, mild, and moderate COVID-19 in home isolation based on the empirical evidence generated on the …
BACKGROUND: During the second wave of the COVID-19 pandemic in India, the Ministry of Ayush conducted a community study to provide th …
Impact of AYUSH 64 as an adjunctive to standard of care in mild COVID 19 - An open-label randomized controlled pilot study.
Thakar A, Goyal M, Bhinde S, Chhotala Y, Panara K, Chaudhari S. Thakar A, et al. J Ayurveda Integr Med. 2022 Jul-Sep;13(3):100587. doi: 10.1016/j.jaim.2022.100587. Epub 2022 May 18. J Ayurveda Integr Med. 2022. PMID: 35600633 Free PMC article.
AIM: To evaluate the preliminary efficacy and safety of AYUSH 64 as an add-on to standard of care in mild COVID19 patients. ...The proportion of asymptomatic patients progressing to the symptomatic stage is lower in AYUSH 64 group [OR, 0.68 (CI, 0.17-2 …
AIM: To evaluate the preliminary efficacy and safety of AYUSH 64 as an add-on to standard of care in mild COVID19 patients. .. …
AYUSH-64 as an adjunct to standard care in mild to moderate COVID-19: An open-label randomized controlled trial in Chandigarh, India.
Singh H, Srivastava S, Yadav B, Rai AK, Jameela S, Muralidharan S, Mohan R, Chaudhary S, Singhal R, Rana R, Khanduri S, Sharma BS, Chandrasekhararao B, Srikanth N, Chaturvedi S. Singh H, et al. Complement Ther Med. 2022 Jun;66:102814. doi: 10.1016/j.ctim.2022.102814. Epub 2022 Feb 8. Complement Ther Med. 2022. PMID: 35149205 Free PMC article. Clinical Trial.
OBJECTIVE: To determine the therapeutic efficacy and safety of AYUSH-64 as an add-on to standard care in mild to moderate COVID-19. DESIGN SETTING, AND INTERVENTIONS: This open-label randomized controlled parallel-group trial was conducted at a designated COVID care …
OBJECTIVE: To determine the therapeutic efficacy and safety of AYUSH-64 as an add-on to standard care in mild to moderate COVI …
23 results